Medtech in 2021: Equipping for a Post-COVID-19 Rebound

article image

In 2021, medtech will grapple with ways to capture the pandemic rebound opportunity through value-adding new technologies and responsiveness to the complexities and diversity of the shifting US healthcare system. In late January, a panel of experts spoke with MedTech Strategist about these challenges.

On January 22, MedTech Strategist convened a panel to discuss the outlook for the medical device industry as it emerges from pandemic. Panelists included Jacob Paul, SVP Medtronic Cranial and Spinal Technologies, Jim Archetto, VP Guamard Scientific, Ryan Zimmerman, Managing Director and Medtech Analyst, BTIG, and Brian Chapman, Principal at ZS Associates.

Subscribers can watch the panel video below.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: